RESUMO
The objective of this study was to evaluate the effect of eubiotics on the intestinal morphology of broilers. For this purpose, 125 birds were divided into six groups with two replicates each (10 birds in each replicate). Group A was given a Basal diet. All groups except group A were challenged with Salmonella enterica serovar Enteritidis. Group B was provided the basal diet, group C was fed a Probiotic-added diet; group D was fed a Prebiotics-based diet; group E was given essential oils plus the basal diet; and group F was provided with organic acids plus the basal diet. Two separate experiments were carried out for Salmonella recovery, checking the cecal tonsils and conducting an intestinal pathomorphic evaluation. Villus length, villus width, villus surface area, and crypt depth were measured by micrometry. There was an overall improvement (p<0.05) in intestinal morphometric parameters for all the treatment groups except for the negative control group, which showed the lowest villus height and villus depth values. Maximum villus height (p<0.05) of the duodenum was achieved by group E, which was fed a diet containing essential oils, whereas a maximum villus surface area index (p<0.05) was recorded for the birds of Group D, which were fed a diet containing prebiotics. Maximum villus height (p<0.05) and surface area index in ileum mucosa was recorded (p<0.05) in the birds of group D (treated with prebiotics). It is concluded that there is an overall increase in the gut histology of broilers fed non-antibiotic based feed.(AU)
Assuntos
Animais , Galinhas/fisiologia , Aditivos Alimentares/efeitos adversos , Salmonella enterica/crescimento & desenvolvimentoRESUMO
Gallbladder cancer (GBC) is an aggressive gastrointestinal malignancy with no approved targeted therapy. Here, we analyze exomes (n = 160), transcriptomes (n = 115), and low pass whole genomes (n = 146) from 167 gallbladder cancers (GBCs) from patients in Korea, India and Chile. In addition, we also sequence samples from 39 GBC high-risk patients and detect evidence of early cancer-related genomic lesions. Among the several significantly mutated genes not previously linked to GBC are ETS domain genes ELF3 and EHF, CTNNB1, APC, NSD1, KAT8, STK11 and NFE2L2. A majority of ELF3 alterations are frame-shift mutations that result in several cancer-specific neoantigens that activate T-cells indicating that they are cancer vaccine candidates. In addition, we identify recurrent alterations in KEAP1/NFE2L2 and WNT pathway in GBC. Taken together, these define multiple targetable therapeutic interventions opportunities for GBC treatment and management.
Assuntos
Proteínas de Ligação a DNA/genética , Mutação da Fase de Leitura , Neoplasias da Vesícula Biliar/genética , Predisposição Genética para Doença/genética , Proteínas Proto-Oncogênicas c-ets/genética , Fatores de Transcrição/genética , Vacinas Anticâncer/genética , Vacinas Anticâncer/imunologia , Chile , Proteínas de Ligação a DNA/imunologia , Proteínas de Ligação a DNA/metabolismo , Neoplasias da Vesícula Biliar/diagnóstico , Neoplasias da Vesícula Biliar/metabolismo , Perfilação da Expressão Gênica/métodos , Regulação Neoplásica da Expressão Gênica , Genômica/métodos , Humanos , Índia , Proteína 1 Associada a ECH Semelhante a Kelch/genética , Proteína 1 Associada a ECH Semelhante a Kelch/metabolismo , Fator 2 Relacionado a NF-E2/genética , Fator 2 Relacionado a NF-E2/metabolismo , Proteínas Proto-Oncogênicas c-ets/imunologia , Proteínas Proto-Oncogênicas c-ets/metabolismo , República da Coreia , Fatores de Transcrição/imunologia , Fatores de Transcrição/metabolismo , Via de Sinalização Wnt/genética , beta Catenina/genética , beta Catenina/metabolismoRESUMO
BACKGROUND: The Roche Cobas chemistry analyzer's hemolysis index (HI) check function can directly report hemoglobin (Hb) concentrations. We aimed to validate the HI check function for the measurement of plasma cell-free Hb. METHODS: Plasma samples (6 µl) were taken by the analyzer and diluted in normal saline to measure the absorbance for Hb at 570 and 600 nm. Hb concentrations were calculated based on the molar extinction coefficient. Imprecision, lower limit of quantification (LLOQ), and analytical measurement range (AMR) of the assay were evaluated. The accuracy was determined by comparing the results between the new method and an existing spectrophotometric method. We further studied interference of icterus and lipemia and carryover. The performance of the assay in proficiency testing was also evaluated. The reference range was transferred from the existing method. RESULTS: Within-run and total CVs were 1.7%-4.2% and 2.1%-7.0%, respectively (n = 20). The LLOQ was 11 mg/dL (CV = 8.1%) with the upper limit of AMR of 506 mg/dL. The results of the new method correlated well with the existing reference assay: Y (new method) = 0.974 x (reference method) + 4.9, r = 0.9990, n = 52. Bilirubin with a concentration up to 60 mg/dL and lipemic index up to 389 did not show significant interference. No significant carryover was detected. The average standard deviation index in proficiency testing was 0.03 ± 0.29. The reference range was <22 mg/dL. CONCLUSIONS: Plasma cell-free Hb measurement using the HI check function meets the analytical requirements of the plasma cell-free Hb assays. It is simple and cost-effective.
Assuntos
Testes Hematológicos/métodos , Hemoglobinas/análise , Hemólise , Automação Laboratorial , Bilirrubina/sangue , Testes Hematológicos/instrumentação , Testes Hematológicos/normas , Humanos , Ensaio de Proficiência Laboratorial , Valores de Referência , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
Objetivo. La alergia alimentaria es un problema de salud pública. Los objetivos fueron determinar la asociación entre la alergia a la proteína de la leche de vaca (APLV) y la vitamina 25(OH)D en los lactantes diagnosticados con APLV y la asociación entre la 25(OH)D y (a) tamaño de la zona indurada en la prueba intraepidérmica, (b) IgE específica para leche y (c) IgE específica para caseína. Métodos. Estudio de casos y controles prospectivo, observacional con niños < 2 años con APLV confirmada mediante prueba de exposición oral al alimento. Se incluyó a lactantes sanos como controles. La concentración sérica de 25(OH)D se obtuvo en ambos grupos. Se estudió la correlación entre la vitamina D y la APLV. Resultados. Entre los pacientes (n: 56), el 41,1 % (n: 23) tenía alergia mediada por la IgE y el 58,9 % (n: 33), alergia no mediada por la IgE. No hubo diferencias estadísticamente significativas entre los grupos con APLV y de referencia (n: 55) en la 25(OH)D (33,85 ± 16,18 ng/ml, 30,70 ± 14,90 ng/ml; respectivamente, p : 0,289). No hubo diferencias estadísticamente significativas entre los grupos según la 25(OH)D (adecuada, insuficiencia, deficiencia; p = 0,099). Con la prueba intraepidérmica, se determinó una correlación negativa sin significancia estadística entre la zona indurada del antígeno de la leche y la 25(OH)D (p: 0,794; r = -0,037). Conclusiones. No se observaron diferencias significativas en la 25(OH)D entre ambos grupos. Estos resultados no respaldan la solicitud de rutina de análisis de 25(OH)D en los lactantes con APLV.
Aim. Food allergy is an important public health concern with an increasing prevalence. The objectives were to determine the possible association between cow's milk protein allergy (CMPA) and 25(OH)D (vitamin-D) levels of infants with an initial diagnosis of CMPA and the association between 25(OH)D levels and (a) SPT (skin prick test) induration size, (b) specific IgE to milk, (c) specific IgE to casein. Methods. Prospective, observational, case control study; the study group was composed of children < 2 years of age with a diagnosis of CMPA confirmed by an oral food challenge test. Healthy infants were enrolled as controls. Serum 25(OH) D levels were obtained at the initial workup in both groups. The correlation of vitamin-D levels was investigated in the development of CMPA. Results. Among the study group of patients (n:56) 41,1% (n:23) had IgE-mediated and 58,9% (n:33) had non-IgE-mediated allergies There were no statistically significant differences between the CMPA and control groups (n: 55), in terms of serum 25(OH)D levels (33.85 ± 16.18ng/ml, 30.70 ± 14.90ng/ml; respectively, p:0.289). No statistically significant difference was found between study and controls according to 25(OH) D levels (adequate, insufficiency, deficiency; p=0.099). In the SPT of the CMPA group, a negative weak correlation without statistical significance was determined between the induration diameter of milk antigen and serum levels of 25(OH)D (p:0,794; r= -0,037). Conclusions. No significant difference was found in serum 25 (OH)D levels between infants with CMPA and healthy controls. Our results do not support the routine request for 25(OH)D levels in pediatric age CMPA patients at their initial workup.
Assuntos
Humanos , Recém-Nascido , Lactente , Vitamina D , Hipersensibilidade a Leite , Hipersensibilidade AlimentarRESUMO
AIM: Food allergy is an important public health concern with an increasing prevalence. The objectives were to determine the possible association between cow's milk protein allergy (CMPA) and 25(OH)D (vitamin-D) levels of infants with an initial diagnosis of CMPA and the association between 25(OH)D levels and (a) SPT (skin prick test) induration size, (b) specific IgE to milk, (c) specific IgE to casein. METHODS: Prospective, observational, case control study; the study group was composed of children < 2 years of age with a diagnosis of CMPA confirmed by an oral food challenge test. Healthy infants were enrolled as controls. Serum 25(OH) D levels were obtained at the initial workup in both groups. The correlation of vitamin-D levels was investigated in the development of CMPA. RESULTS: Among the study group of patients (n:56) 41,1% (n:23) had IgE-mediated and 58,9% (n:33) had non-IgE-mediated allergies There were no statistically significant differences between the CMPA and control groups (n: 55), in terms of serum 25(OH)D levels (33.85 ± 16.18ng/ml, 30.70 ± 14.90ng/ml; respectively, p:0.289). No statistically significant difference was found between study and controls according to 25(OH) D levels (adequate, insufficiency, deficiency; p=0.099). In the SPT of the CMPA group, a negative weak correlation without statistical significance was determined between the induration diameter of milk antigen and serum levels of 25(OH)D (p:0,794; r= -0,037). CONCLUSIONS: No significant difference was found in serum 25 (OH)D levels between infants with CMPA and healthy controls. Our results do not support the routine request for 25(OH)D levels in pediatric age CMPA patients at their initial workup.
Objetivo. La alergia alimentaria es un problema de salud pública. Los objetivos fueron determinar la asociación entre la alergia a la proteína de la leche de vaca (APLV) y la vitamina 25(OH)D en los lactantes diagnosticados con APLV y la asociación entre la 25(OH)D y (a) tamaño de la zona indurada en la prueba intraepidérmica, (b) IgE específica para leche y (c) IgE específica para caseína. Métodos. Estudio de casos y controles prospectivo, observacional con niños < 2 años con APLV confirmada mediante prueba de exposición oral al alimento. Se incluyó a lactantes sanos como controles. La concentración sérica de 25(OH)D se obtuvo en ambos grupos. Se estudió la correlación entre la vitamina D y la APLV. Resultados. Entre los pacientes (n: 56), el 41,1 % (n: 23) tenía alergia mediada por la IgE y el 58,9 % (n: 33), alergia no mediada por la IgE. No hubo diferencias estadísticamente significativas entre los grupos con APLV y de referencia (n: 55) en la 25(OH)D (33,85 ± 16,18 ng/ml, 30,70 ± 14,90 ng/ ml; respectivamente, p : 0,289). No hubo diferencias estadísticamente significativas entre los grupos según la 25(OH)D (adecuada, insuficiencia, deficiencia; p = 0,099). Con la prueba intraepidérmica, se determinó una correlación negativa sin significancia estadística entre la zona indurada del antígeno de la leche y la 25(OH)D (p: 0,794; r = -0,037). Conclusiones. No se observaron diferencias significativas en la 25(OH)D entre ambos grupos. Estos resultados no respaldan la solicitud de rutina de análisis de 25(OH)D en los lactantes con APLV.
Assuntos
Imunoglobulina E/imunologia , Hipersensibilidade a Leite/imunologia , Proteínas do Leite/imunologia , Vitamina D/análogos & derivados , Estudos de Casos e Controles , Feminino , Humanos , Lactente , Masculino , Estudos Prospectivos , Testes Cutâneos , Vitamina D/sangueRESUMO
A study was conducted to determine the effects of flaxseed supplementation on performance, carcass traits, and hindleg fatty acid composition of guinea pigs. Sixty male and female weaned guinea pigs (1 month old, five animals/cage) were blocked by sex and bodyweight and randomly fed 0 (control) or 100 g/kg flaxseed concentrate diets (15 g/animal) plus ad libitum fresh alfalfa for 30 days. Results showed that flaxseed supplementation had no influence on animal performance. However, final body weight (P = 0.035), total feed intake (P = 0.019), and body weight gain (P < 0.001) were higher in male than female guinea pigs. Similar results were also observed for carcass composition (i.e., hot, chilled, and reference carcass weights). Inclusion of flaxseed reduced saturated (P < 0.001), mono-unsaturated (P = 0.004), and increased (P < 0.001) polyunsaturated (PUFA) fatty acid concentrations in hindlegs. Concentrations of linolenic acid and n-3 PUFA increased (P < 0.001) by 49.7 and 37.1%, respectively as a result of flaxseed inclusion. It was concluded that feeding flaxseed to guinea pigs at 100 g/kg of the concentrate diets improves meat PUFA concentrations with no adverse effects on performance or carcass composition.
Assuntos
Ingestão de Alimentos , Ácidos Graxos/análise , Linho/metabolismo , Cobaias/fisiologia , Membro Posterior , Carne/análise , Aumento de Peso , Ração Animal/análise , Animais , Dieta/veterinária , Suplementos Nutricionais/análise , Ingestão de Alimentos/efeitos dos fármacos , Feminino , Linho/química , Cobaias/crescimento & desenvolvimento , Membro Posterior/química , Membro Posterior/efeitos dos fármacos , Masculino , Peru , Distribuição Aleatória , Sementes/química , Aumento de Peso/efeitos dos fármacosRESUMO
Gallbladder cancer (GBC) is a lethal cancer with poor prognosis associated with high invasiveness and poor response to chemotherapy and radiotherapy. New therapeutic approaches are urgently needed in order to improve survival and response rates of GBC patients. We screened 130 small molecule inhibitors on a panel of seven GBC cell lines and identified the HSP90 inhibitor 17-AAG as one of the most potent inhibitory drugs across the different lines. We tested the antitumor efficacy of 17-AAG and geldanamycin (GA) in vitro and in a subcutaneous preclinical tumor model NOD-SCID mice. We also evaluated the expression of HSP90 by immunohistochemistry in human GBC tumors.In vitro assays showed that 17-AAG and GA significantly reduced the expression of HSP90 target proteins, including EGFR, AKT, phospho-AKT, Cyclin B1, phospho-ERK and Cyclin D1. These molecular changes were consistent with reduced cell viability and cell migration and promotion of G2/M cell cycle arrest and apoptosis observed in our in vitro studies.In vivo, 17-AAG showed efficacy in reducing subcutaneous tumors size, exhibiting a 69.6% reduction in tumor size in the treatment group compared to control mice (p < 0.05).The HSP90 immunohistochemical staining was seen in 182/209 cases of GBC (87%) and it was strongly expressed in 70 cases (33%), moderately in 58 cases (28%), and weakly in 54 cases (26%).Our pre-clinical observations strongly suggest that the inhibition of HSP90 function by HSP90 inhibitors is a promising therapeutic strategy for gallbladder cancer that may benefit from new HSP90 inhibitors currently in development.